<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Neuroendocrine <z:mp ids='MP_0002038'>carcinomas</z:mp> (NECs) are rare <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with an increasing incidence </plain></SENT>
<SENT sid="1" pm="."><plain>Oncogenetic pathways of colorectal NEC are still poorly understood, and no treatment standards are available for these rare <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We analyzed retrospectively the clinical records and histology of 12 patients with colorectal NEC </plain></SENT>
<SENT sid="3" pm="."><plain>KRAS and BRAF mutations were investigated after the dissection of exoendocrine and neuroendocrine components </plain></SENT>
<SENT sid="4" pm="."><plain>ALK alterations and EML4-ALK transcripts were detected by in-situ hybridization and determination of fusion transcripts, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At the time of diagnosis, the mean age of the patients was 60 years (40-79) and 10 patients had synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>A transient response occurred in two patients and one patient treated with <z:chebi fb="2" ids="27899">cisplatin</z:chebi>-<z:chebi fb="0" ids="4911">etoposide</z:chebi> or fluoropyrimidine-<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">Tumor progression</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> occurred in 11 of 12 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Ten <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> contained an exocrine component, accounting for 5-70% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, and the other two contained an amphicrine component </plain></SENT>
<SENT sid="9" pm="."><plain>BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D) </plain></SENT>
<SENT sid="10" pm="."><plain>DNA was obtained from both exocrine and <z:chebi fb="32" ids="24621">endocrine</z:chebi> components in seven cases, and the BRAF/KRAS status was identical in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="11" pm="."><plain>Split of the ALK locus was detected in a minority of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in two of eight cases, but EML4-ALK transcripts were absent </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The association of an exocrine component in <z:hpo ids='HP_0000001'>all</z:hpo> cases and the similar profile of BRAF/KRAS mutations indicate that colorectal NEC may correspond to a high-grade transformation of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>New chemotherapy regimens using targeted therapies should be assessed in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>